| Prev Close | 46.27 |
| Open | 46.10 |
| Day Low/High | 46.10 / 48.82 |
| 52 Wk Low/High | 30.15 / 64.94 |
| Volume | 1.04M |
| Avg Volume | 762.50K |
Global Blood Therapeutics Inc. (GBT)
48.36
2.10
4.50
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 60.02M |
| Market Cap | 2.82B |
| EPS | -3.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
There Are Signs of Improved Technical Action and Stock Picking
China trade issue is no longer dominating the action.
Sector Liquidations Provide Great Opportunity but Short Term Pain Is Tremendous
There is no respite today from the poor price action in individual stocks.
I Like These 2 Smaller Name Biotech Stocks
I still believe it will be a big year for buyouts across the biotech industry.
Fear of Missing Out Outweighs Fear of Trump Political Fallout
If the market wanted an excuse to sell off it had it.
Strength in Growth Names Is Giving the Market a More Upbeat Feel
Apple in particular is helping the bullish cause.
Heineken Stock Boosted By China Deal as Jefferies Downgrades
If there is any good news on trade the potential for more market upside is strong.
Play the Hemorrhage in Global Blood's Stock
I see the $32.50 to $35 area as major support for GBT.
These Biotechs Are Movers Today
The market is down across the board as one might expect given escalating trade tensions today. However, losses are slight in this context in the first hour of trading. Given the option expiration date, volatility could pick up later in the day. Some...
Even Momentum Traders Should Study Stock Charts
You don't have to 'believe' in technical analysis to use it to set your exit and entry points.
Many Names on My Radar
There is no question that we are becoming extended and ripe for some profit taking.
Having Some Good Luck With Biotech Names
Overall it is still a positive day but the action is sloppy.
Markets Make an Art of Unpredictability
Oil isn't the only reason stocks are higher.
Markets Confused by Trump's Upcoming Iran Decision
No matter what happens with Iran, it is not going to be a major market positive.
5 Stocks That Are Showing Signs of Reversing
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
With an Eye on Biotech, Here's Today's Trading Thesis
It is important to note that watching for a reversal is much different than being short.
The Confidence in the Dip Buyers Has Weakened
The bears are likely to be increasingly bold if there's a failed bounce.
This Market Badly Needs a Rest
It would be a longer-term positive if the overbought conditions are alleviated.
The Stock Market Is Facing One Big Obstacle Right Now
You have to wonder how much longer we can run without a pullback of at least 2%.
Markets Nicely Off Today's Lows
Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...
Selling Action Is Upon Us
There is still a very strong appetite for individual stocks with momentum.
Focused on Stock Picking Through This Volatility
I'm trying not to be sucked into the market-timing game and am looking mainly at setups in individual stocks.
The Return of Stock Market Volatility Can Create Stellar Opportunities
But you need to be selective and have discipline.
Markets Get Back to Business as Usual
U.S. stocks move higher after early slip, as investors digest Apple's latest results.
DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
Global Blood Therapeutics Makes a Bold Move
This stock's old highs may come into play.
Biotech Names Flexing Their Muscles
There's action in Global Blood Therapeutics and Antares Pharma.
Hoping for Negative Seasonality, but Market's Not Holding Its Breadth
The major indices barely budged intraday this week, as we had the narrowest trading range ever.